The GSDMD Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human GSDMD gene in the A2780 ovarian cancer epithelial cell line. This mixed-cell pool results from bulk Cas9-mediated editing, providing a genetically diverse loss-of-function model that avoids single-clone artifacts while maintaining efficient target-gene disruption for downstream assays.
Derived from an untreated patient with ovarian carcinoma, the A2780 cell line is a well-established epithelial model retaining cisplatin sensitivity. Its utility in cancer research spans tumorigenesis studies, drug response profiling, and signaling pathway analysis. The cells?? compatibility with CRISPR/Cas9 technology facilitates targeted genetic modifications, enabling detailed mechanistic investigations in an ovarian cancer context.
GSDMD functions as the executer of pyroptosis, a lytic programmed cell death pathway. Inflammasome complexes??including NLRP3, NLRC4, and AIM2??recruit and activate caspase-1 through the adaptor ASC, while caspase-4 and caspase-5 are directly activated by intracellular LPS. These inflammatory caspases cleave GSDMD, liberating the N-terminal gasdermin domain, which inserts into the plasma membrane and oligomerizes to form pores. Pore formation leads to loss of osmotic homeostasis, cell swelling, membrane rupture, and the extracellular release of IL-1?? and IL-18, along with damage-associated molecular patterns. Consequently, GSDMD sits at the convergence point of canonical and non-canonical inflammasome signaling, directly interacting with caspase-1, caspase-4, and caspase-5 to execute pyroptotic death and cytokine secretion.
In the context of ovarian cancer, pyroptosis has been implicated in chemotherapeutic responses and tumor microenvironment modulation. A2780 cells, being cisplatin-sensitive, offer a relevant system to study whether GSDMD-mediated pyroptosis contributes to drug-induced cytotoxicity or alternatively fosters inflammation-driven tumor progression. The knockout model enables researchers to uncouple pyroptotic cell death from inflammasome-dependent cytokine release, providing insights into how these processes impact tumor immunity, metastasis, and therapy resistance.
Researchers can validate GSDMD disruption via western blot (using antibodies against full-length and cleaved fragments) and RT-qPCR for transcript analysis. Pyroptosis readouts include LDH release, propidium iodide uptake, and imaging of membrane pores. ELISA assays quantify IL-1?? and IL-18 secretion, while caspase-1 activity assays and co-immunoprecipitation with caspases confirm upstream pathway engagement. These polyclonal knockout cells are well-suited for screening small-molecule modulators of pyroptosis or evaluating combinatorial treatment strategies. For technical support or further product information, please contact Ascent Research.
